title: Response to comment on Ågren et al. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes care 2014;37:2007-2014.
authors.affiliation: Coagulation Unit, Division of Haematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden anna.agren@karolinska.se.
authors.forename: Anna
authors.initials: A
authors.lastname: Agren
authors.affiliation: Division of Internal Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
authors.forename: Gun
authors.initials: G
authors.lastname: Jörneskog
authors.affiliation: Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
authors.forename: Graciela
authors.initials: G
authors.lastname: Elgue
authors.affiliation: Division of Cardiovascular Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
authors.forename: Peter
authors.initials: P
authors.lastname: Henriksson
authors.affiliation: Division of Cardiovascular Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
authors.forename: Håkan
authors.initials: H
authors.lastname: Wallen
authors.affiliation: Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
authors.forename: Björn
authors.initials: B
authors.lastname: Wiman
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D005260:Female; D005337:Fibrin / Q000378:metabolism*; D006801:Humans; D008297:Male; D000979:alpha-2-Antiplasmin / Q000378:metabolism*
chemical_list: D000979:alpha-2-Antiplasmin; D005337:Fibrin